Actelion Will Take Novel Sleep Therapy Into Phase III This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss company, known for its pulmonary hypertension dominance, welcomes awareness-raising competition from new entrants like Gilead, CFO Oakley says.